Key topics in advanced therapy manufacturing: quality, safety, and supply

Published: 24 November 2021
Podcast
Jeffrey Hung, PhD,
Professor Daniel C. Smith, PhD, FRSB,
Horst Ruppach, PhD

Jeffrey Hung

General Manager, Vigene Biosciences, a Charles River Company

Daniel Smith

Executive Director, Global Cell and Gene Therapy Portfolio, Cobra Biologics, a Charles River Company

Horst Ruppach

Executive Director, Scientific and Portfolio, Global Biologics, Charles River

Listen to the full podcast:


Listen to each individual question and answer:













Authorship & Conflict of Interest

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest.

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.

Article & copyright information

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2021 Charles River. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: Invited.

Interview conducted: Nov 8 2021; Publication date: Nov 23 2021.